Acute Myeloid Leukemia
Conditions
Interventions
Group 1: Patients treated with H(E)AG + Venetoclax + Azacitidine:None
Group 2: Patients treated with H(E)AG alone:None
Sponsors
The second affiliated hospital of the army medical university
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Clinical diagnosis of relapsed and refractory AML Definition of relapsed/refractory: 1) Recurrent disease: Leukemia cells or blasts in the bone marrow >=5% in the peripheral blood after complete remission (CR) of AML (except for other reasons such as bone marrow regeneration after consolidation chemotherapy) or leukemia cell infiltration outside the medulla. 2) MRD recurrence: from MRD negative to MRD positive; 3) Refractory disease: naïve cases that have failed to respond to two courses of treatment with standard regimens; After CR after consolidation and intensive therapy, recurrence within 12 months; Those who relapse after 12 months and do not respond to conventional chemotherapy; Those with two or more recurrences; Extramedullary leukemia persistent. 4) Patients with newly diagnosed AML do not respond within one course of treatment (2) The date of relapse or refractory is defined as the date of sampling on the first bone marrow cytogenetics or molecular report. (3) Age>=18 years, <=70 years; (4) Patients admitted to the hospital for treatment; (5) The patient agrees to participate in this study and signs the informed consent form; (6) Detailed diagnosis and treatment and follow-up data can be obtained
Exclusion criteria
Exclusion criteria: (1) Acute promyelocytic leukemia; (2) Patients with other untreated malignancies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The modified composite complete remission (mCRc) rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival(OS);Progression-Free Survival (PFS);Duration of Response (DOR);Adverse Events (Safety);Overall Response Rate (ORR); | — |
Countries
China
Contacts
Public ContactWen Qin
The second affiliated hospital of the army medical university
Outcome results
None listed